KLOW Peptide Dosage: Chart & Reconstitution Guide

KLOW Peptide Dosage: Chart & Reconstitution Guide. KLOW peptide dosage chart: reconstitute the 80mg vial with 2mL BAC water, standard 5–10 unit research doses, and per-component breakdown. Key Takeaways KLOW is an 80mg four-peptide research blend labeled 50/10/10/10: GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, and KPV 10mg. Standard reconstitution is 2mL of bacteriostatic water into the 80mg vial, giving a 40mg/mL concentration where each U-100 unit (0.01mL) delivers 0.4mg of total blend. Typical documented research doses are 5–10 units (2–4mg of blend) on a U-100 insulin syringe. KPV is what distinguishes KLOW from the GLOW blend — it adds an anti-inflammatory component that GLOW does not contain. KLOW and every component are research compounds. None are FDA-approved for human use, and this article reports documented protocols for research models, not medical advice. KLOW is an 80mg, four-peptide research blend , and the most common documented reconstitution is 2mL of bacteriostatic water added to the vial, producing a 40mg/mL solution. On a U-100 insulin syringe, researchers typically draw 5 to 10 units per administration, which equals 2mg to 4mg of total blend . Use the interactive KLOW dosage calculator to model other water volumes, U-100 units, and the amount of each component in a total blend draw. This guide reports the reconstitution math, a full KLOW dosage chart, and a per-component breakdown so the numbers can be checked against published research ranges for each peptide. Throughout, "dose," "protocol," and "cycle" describe what is documented in research and community protocols, not clinical prescriptions. KLOW is a laboratory research blend, and every figure below is provided so researchers can understand and reproduce the reported handling — not as guidance for human use. For the regulatory context around the isolated copper peptide, see our GHK-Cu FDA approval status guide. What Is in KLOW: Composition of the 80mg Blend KLOW is a fixed-ratio blend labeled "50/10/10/10," which refers to the milligram content of each of its four peptides in the 80mg vial. Because the ratio is fixed, every unit you draw contains all four peptides in the same proportion — you cannot dose one component without dosing the others. Peptide Amount % of Blend GHK-Cu (copper tripeptide) 50 mg 62.5% BPC-157 10 mg 12.5% TB-500 (thymosin beta-4 fragment) 10 mg 12.5% KPV (lysine-proline-valine) 10 mg 12.5% Total 80 mg 100% In a research context, each component maps to a distinct literature: GHK-Cu is the most-studied copper tripeptide, investigated for extracellular matrix remodeling and collagen-related signaling (Pickart & Margolina, 2018) . BPC-157 is a gastric-derived pentadecapeptide studied in connective-tissue and gut healing models. TB-500 is a synthetic fragment of thymosin beta-4 examined for cell migration and tissue repair. KPV is the C-terminal tripeptide of alpha-MSH studied for anti-inflammatory activity (Grabbe et al., 2003) . That KPV component is the single feature that distinguishes KLOW from the more common GLOW blend. GLOW contains only GHK-Cu, BPC-157, and TB-500; KLOW adds KPV as an anti-inflammatory fourth peptide. Researchers working with the three-peptide sibling should use the 70mg GLOW dosage chart , while our GHK-Cu vs KLOW peptide comparison covers why blend transparency and per-component COAs matter more than the brand name. How to Reconstitute KLOW (80mg Vial) KLOW ships as a lyophilized (freeze-dried) powder that must be reconstituted before use in any research model. The documented standard is 2mL of bacteriostatic water added slowly to the 80mg vial. Dividing 80mg by 2mL gives a working concentration of 40mg/mL , which is the number every dosing calculation below is built on. Vial Size BAC Water Added Concentration 10-Unit Dose 80 mg 2 mL 40 mg/mL 4 mg blend To reconstitute, aim the bacteriostatic water down the inside wall of the vial rather than directly onto the powder pellet, then gently swirl until fully dissolved. Do not shake — agitation can shear peptide bonds and denature the more delicate components. The solution should be clear once dissolved. Bacteriostatic water is the standard diluent because its benzyl alcohol content limits microbial growth over the multi-week use window described below. KLOW Dosage Chart This is the centerpiece reference. Because KLOW is reconstituted to 40mg/mL, each U-100 insulin unit (0.01mL) delivers 0.4mg of total blend. The chart converts common research amounts into syringe units and milliliter volumes. Total Blend Dose Syringe Units (U-100) Volume (mL) 1 mg 2.5 units 0.025 mL 2 mg 5 units 0.05 mL 3 mg 7.5 units 0.075 mL 4 mg 10 units 0.1 mL 5 mg 12.5 units 0.125 mL These conversions assume a U-100 insulin syringe , where 1mL equals 100 units. If a protocol lands between visible marks, round to the nearest graduation on the syringe barrel — the difference of half a unit is well within the tolerance of research handling. The most frequently documented KLOW range is the 5-to-10-unit band (2–4mg of blend). Per-Component Dose Breakdown per Injection Because the blend is fixed-ratio, it is useful to see exactly how much of each peptide lands in a 5-unit versus a 10-unit draw. At 40mg/mL, GHK-Cu makes up 62.5% of every microliter, and the three repair/anti-inflammatory peptides each contribute 12.5%. Peptide Per 5 Units (2mg blend) Per 10 Units (4mg blend) GHK-Cu 1.25 mg 2.50 mg KPV 250 mcg 500 mcg BPC-157 250 mcg 500 mcg TB-500 250 mcg 500 mcg At the 10-unit dose, all four components land within commonly cited research ranges: GHK-Cu at 2.5mg, and BPC-157, TB-500, and KPV each at 500mcg. This is part of why the blend is formulated at the 50/10/10/10 ratio — a single 10-unit draw brings every peptide into its typical research window simultaneously. Frequency and Cycling Protocols The following schedules are reported from community and research protocols. They describe how the blend has been documented in practice, not a prescribed regimen. A common two-phase structure is used: Loading phase (weeks 1–4): 10 units, 5 days per week. Maintenance phase (weeks 5–12): 5–10 units, 3 days per week. Typical cycle: 8–12 weeks on, followed by 4–8 weeks off. The loading phase front-loads the tissue-repair and copper-peptide exposure, while maintenance tapers frequency once the initial window has passed. The on/off cycle structure is standard across multi-peptide repair blends. For practical injection-site context that also applies to GHK-Cu-heavy blends like KLOW, see our guide on where to inject GHK-Cu . How Long a KLOW Vial Lasts A reconstituted 80mg vial at 40mg/mL holds 200 units of solution (2mL × 100 units/mL). During a loading phase of 10 units five times weekly — 50 units per week — a single vial covers roughly four weeks . Across a full 12-week cycle, factoring the lighter maintenance dosing, expect to use two to three vials . Scenario Weekly Units Vial Duration Loading (10 units × 5/wk) 50 units ~4 weeks per vial Full 12-week cycle Variable ~2–3 vials Storage and Stability Store the reconstituted KLOW vial refrigerated at 2–8°C and use it within approximately 28 days of reconstitution, consistent with the bacteriostatic preservation window. Keep unreconstituted lyophilized vials cold and protected from light; the freeze-dried powder is considerably more stable than the solution. Avoid repeated temperature cycling, and never freeze a reconstituted vial, which can precipitate the peptides out of solution. Where to Get Research-Grade KLOW Because KLOW is a four-peptide blend, sourcing quality depends on a vendor disclosing every component amount and providing batch-specific certificates of analysis for the full formula — not a single generic purity figure. Peptide Partners lists the KLOW peptide blend as a research-use product with the 50/10/10/10 composition documented above. Amino Club is another vendor that publishes lot-matched COAs on its GHK-Cu, BPC-157, and TB-500 stock; our Amino Club review covers whether that testing holds up, and our wider rundown of grey market peptide suppliers shows which vendors document blends properly. If you source the blend from Peptide Partners, the current Peptide Partners discount code is listed on our dedicated page. Safety and Research-Use Considerations KLOW is sold for laboratory research use only and is not intended for human consumption, diagnosis, or treatment . None of its four peptides — GHK-Cu, BPC-157, TB-500, or KPV — is FDA-approved as a drug. Documented observations in research models include gastrointestinal effects and injection-site reactions such as transient redness or irritation, which are commonly reported with subcutaneous peptide handling. The fixed-ratio nature of the blend also means components cannot be titrated independently: any adjustment scales all four peptides together. Nothing in this article is medical advice. Researchers should follow appropriate laboratory safety protocols and applicable regulations. For broader sourcing and handling context, see our research peptide safety guide . Frequently Asked Questions How much BAC water do you add to an 80mg KLOW vial? The documented standard is 2mL of bacteriostatic water, which reconstitutes the 80mg vial to a 40mg/mL working concentration. At that concentration, each U-100 unit delivers 0.4mg of total blend. How many units is a standard KLOW dose? The most commonly documented range is 5 to 10 units on a U-100 insulin syringe, equal to 2mg to 4mg of total blend. Ten units is the upper end of the typical research window. How often is KLOW dosed? Reported protocols use a loading phase of 10 units five times weekly for the first four weeks, then a maintenance phase of 5–10 units three times weekly for weeks five through twelve. These are documented community/research schedules, not prescriptions. How long does one KLOW vial last? A reconstituted vial holds 200 units. At a loading rate of 50 units per week, one vial lasts about four weeks. A full 12-week cycle typically uses two to three vials. How is KLOW dosing different from GLOW? The reconstitution math is similar, but KLOW adds KPV as a fourth anti-inflammatory peptide that GLOW does not contain. At the same total dose, KLOW delivers a smaller GHK-Cu share by mass because that mass is split across four peptides instead of three. Our guide to the GLOW peptide blend covers the three-peptide composition in full. Can you dose the KLOW components separately? No. KLOW is a fixed-ratio blend, so every draw contains GHK-Cu, BPC-157, TB-500, and KPV in the same 50/10/10/10 proportion. To dose a single peptide independently, a researcher would need to source that compound on its own. What does a 10-unit KLOW dose deliver per peptide? A 10-unit draw (4mg blend) delivers 2.5mg of GHK-Cu and 500mcg each of BPC-157, TB-500, and KPV — placing all four components within their commonly cited research ranges. How should reconstituted KLOW be stored? Refrigerate at 2–8°C and use within roughly 28 days. Keep unreconstituted lyophilized vials cold and away from light, and never freeze the reconstituted solution. What syringe is the KLOW dosage chart based on? All conversions assume a U-100 insulin syringe, where 1mL equals 100 units and each unit is 0.01mL. If a dose falls between marks, round to the nearest graduation on the barrel. References Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. PMID: 18031173 . Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. PMID: 29986520 . Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PMID: 30915550 . Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Ann N Y Acad Sci. 2012. PMID: 22074294 . Grabbe S, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Ann N Y Acad Sci. 2003. PMID: 12750433 . Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID: 18061177 . PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.